Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622635 · ClinicalTrials.gov registry record · Phase 3
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
- 14
- Study locations
NCT00622635 is a Phase 3 study of Chronic Obstructive Pulmonary Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 68 participants, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 7 states.
The verdict
NCT00622635, a Phase 3 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
Conditions Studied
Interventions
- DRUG Indacaterol 300 μg
- DRUG Placebo to indacaterol
- DRUG Salmeterol 50 μg
Study Locations (14)
Other
- Novartis Investigator Site - Genk
- Novartis Investigator Site - Hasselt
- Novartis Investigator Site - Herentals
- Novartis Investigator Site - Alicante
- Novartis Investigator site - Alzira
- Novartis Investigator Site - Madrid
- Novartis Investigator site - Mataró
North Carolina
- Novartis Investigator Site - Charlotte
- Novartis Investigator Site - Raleigh
Illinois
- Novartis Investigator Site - Normal
Kansas
- Novartis Investigator Site - Shawnee Mission
Louisiana
- Novartis Investigator Site - Lafayette
Ohio
- Novartis Investigator site - Cincinnati
South Carolina
- Novartis Investigator Site - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622635
The ClinicalTrials.gov registry entry for NCT00622635 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (96% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 3 interventions - of which Indacaterol 300 μg is the first listed.
NCT00622635 reports 14 study locations spanning 7 distinct geographic areas - top geographies include Other, North Carolina, Illinois.
Frequently Asked Questions
What is clinical trial NCT00622635 about?
NCT00622635 is a clinical study titled "A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)". This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
What is the current status of trial NCT00622635?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2008-01. Estimated completion is 2008-07.
What conditions does trial NCT00622635 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT00622635?
The interventions under investigation include: Indacaterol 300 μg (DRUG), Placebo to indacaterol (DRUG), Salmeterol 50 μg (DRUG).
Who is sponsoring clinical trial NCT00622635?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00622635 being conducted?
This trial has 14 study locations across Illinois, Kansas, Louisiana, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
-
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.